335 related articles for article (PubMed ID: 16492910)
1. Catechol-O-methyltransferase gene polymorphisms in benign prostatic hyperplasia and sporadic prostate cancer.
Tanaka Y; Sasaki M; Shiina H; Tokizane T; Deguchi M; Hirata H; Hinoda Y; Okayama N; Suehiro Y; Urakami S; Kawakami T; Kaneuchi M; Pookot D; Igawa M; Okuyama A; Ishii N; Dahiya R
Cancer Epidemiol Biomarkers Prev; 2006 Feb; 15(2):238-44. PubMed ID: 16492910
[TBL] [Abstract][Full Text] [Related]
2. Genetic polymorphisms of estrogen receptor alpha, CYP19, catechol-O-methyltransferase are associated with familial prostate carcinoma risk in a Japanese population.
Suzuki K; Nakazato H; Matsui H; Koike H; Okugi H; Kashiwagi B; Nishii M; Ohtake N; Nakata S; Ito K; Yamanaka H
Cancer; 2003 Oct; 98(7):1411-6. PubMed ID: 14508827
[TBL] [Abstract][Full Text] [Related]
3. Polymorphisms of catechol-O-methyltransferase in men with renal cell cancer.
Tanaka Y; Hirata H; Chen Z; Kikuno N; Kawamoto K; Majid S; Tokizane T; Urakami S; Shiina H; Nakajima K; Dhir R; Dahiya R
Cancer Epidemiol Biomarkers Prev; 2007 Jan; 16(1):92-7. PubMed ID: 17220335
[TBL] [Abstract][Full Text] [Related]
4. Polymorphisms of estrogen receptor alpha in prostate cancer.
Tanaka Y; Sasaki M; Kaneuchi M; Shiina H; Igawa M; Dahiya R
Mol Carcinog; 2003 Aug; 37(4):202-8. PubMed ID: 12891629
[TBL] [Abstract][Full Text] [Related]
5. Association of vitamin D receptor gene polymorphism with prostate cancer and benign prostatic hyperplasia in a Japanese population.
Habuchi T; Suzuki T; Sasaki R; Wang L; Sato K; Satoh S; Akao T; Tsuchiya N; Shimoda N; Wada Y; Koizumi A; Chihara J; Ogawa O; Kato T
Cancer Res; 2000 Jan; 60(2):305-8. PubMed ID: 10667581
[TBL] [Abstract][Full Text] [Related]
6. p53 Codon 72 and p21 codon 31 polymorphisms in prostate cancer.
Huang SP; Wu WJ; Chang WS; Wu MT; Chen YY; Chen YJ; Yu CC; Wu TT; Lee YH; Huang JK; Huang CH
Cancer Epidemiol Biomarkers Prev; 2004 Dec; 13(12):2217-24. PubMed ID: 15598783
[TBL] [Abstract][Full Text] [Related]
7. Associations between polymorphisms in the steroid 5-alpha reductase type II (SRD5A2) gene and benign prostatic hyperplasia and prostate cancer.
Salam MT; Ursin G; Skinner EC; Dessissa T; Reichardt JK
Urol Oncol; 2005; 23(4):246-53. PubMed ID: 16018939
[TBL] [Abstract][Full Text] [Related]
8. Association of V89L SRD5A2 polymorphism with prostate cancer development in a Japanese population.
Li Z; Habuchi T; Mitsumori K; Kamoto T; Kinoshitu H; Segawa T; Ogawa O; Kato T
J Urol; 2003 Jun; 169(6):2378-81. PubMed ID: 12771801
[TBL] [Abstract][Full Text] [Related]
9. Increased risk of prostate cancer and benign prostatic hyperplasia associated with transforming growth factor-beta 1 gene polymorphism at codon10.
Li Z; Habuchi T; Tsuchiya N; Mitsumori K; Wang L; Ohyama C; Sato K; Kamoto T; Ogawa O; Kato T
Carcinogenesis; 2004 Feb; 25(2):237-40. PubMed ID: 14604900
[TBL] [Abstract][Full Text] [Related]
10. Association of codon 10 polymorphism of the transforming growth factor beta 1 gene with prostate cancer and hyperplasia in an Iranian population.
Omrani MD; Taghipour-Bazargani S; Salari-Lak S; Bagheri M
Urol Int; 2009; 83(3):329-32. PubMed ID: 19829035
[TBL] [Abstract][Full Text] [Related]
11. Angiotensin-converting enzyme insertion/deletion and angiotensin type 1 receptor A1166C polymorphisms as genetic risk factors in benign prostatic hyperplasia and prostate cancer.
Sierra Díaz E; Sánchez Corona J; Rosales Gómez RC; Gutierrez Rubio SA; Vázquez Camacho JG; Solano Moreno H; Morán Moguel MC
J Renin Angiotensin Aldosterone Syst; 2009 Dec; 10(4):241-6. PubMed ID: 20026870
[TBL] [Abstract][Full Text] [Related]
12. Genetic susceptibility of catechol-O-methyltransferase polymorphism in Japanese patients with breast cancer.
Inoue H; Shibuta K; Matsuyama A; Yoshinaga K; Sadanaga N; Ueo H; Barnard GF; Mori M
Oncol Rep; 2005 Sep; 14(3):707-12. PubMed ID: 16077979
[TBL] [Abstract][Full Text] [Related]
13. An association between the allele coding for a low activity variant of catechol-O-methyltransferase and the risk for breast cancer.
Lavigne JA; Helzlsouer KJ; Huang HY; Strickland PT; Bell DA; Selmin O; Watson MA; Hoffman S; Comstock GW; Yager JD
Cancer Res; 1997 Dec; 57(24):5493-7. PubMed ID: 9407957
[TBL] [Abstract][Full Text] [Related]
14. Polymorphisms in genes involved in sex hormone metabolism may increase risk of benign prostatic hyperplasia.
Roberts RO; Bergstralh EJ; Farmer SA; Jacobson DJ; Hebbring SJ; Cunningham JM; Thibodeau SN; Lieber MM; Jacobsen SJ
Prostate; 2006 Mar; 66(4):392-404. PubMed ID: 16302261
[TBL] [Abstract][Full Text] [Related]
15. [Polymorphism of catechol-O-methyltransferase gene in relation to the risk of endometrial cancer].
Zhao XM; Xie MQ; Yang DZ; Wang LA; Li SJ; Zhuang YY; Tang XL
Zhonghua Fu Chan Ke Za Zhi; 2007 Feb; 42(2):116-9. PubMed ID: 17442187
[TBL] [Abstract][Full Text] [Related]
16. Catechol-O-methyltransferase polymorphism is not associated with ovarian cancer risk.
Goodman JE; Lavigne JA; Hengstler JG; Tanner B; Helzlsouer KJ; Yager JD
Cancer Epidemiol Biomarkers Prev; 2000 Dec; 9(12):1373-6. PubMed ID: 11142424
[TBL] [Abstract][Full Text] [Related]
17. Insulin-like growth factor-binding protein-3 gene -202 A/C polymorphism is correlated with advanced disease status in prostate cancer.
Wang L; Habuchi T; Tsuchiya N; Mitsumori K; Ohyama C; Sato K; Kinoshita H; Kamoto T; Nakamura A; Ogawa O; Kato T
Cancer Res; 2003 Aug; 63(15):4407-11. PubMed ID: 12907612
[TBL] [Abstract][Full Text] [Related]
18. Catechol-O-methyltransferase genotype is associated with plasma total homocysteine levels and may increase venous thrombosis risk.
Gellekink H; Muntjewerff JW; Vermeulen SH; Hermus AR; Blom HJ; den Heijer M
Thromb Haemost; 2007 Dec; 98(6):1226-31. PubMed ID: 18064318
[TBL] [Abstract][Full Text] [Related]
19. The Val158Met polymorphism of the catechol-O-methyltransferase gene is associated with the PSA-progression-free survival in prostate cancer patients treated with estramustine phosphate.
Suzuki M; Mamun MR; Hara K; Ozeki T; Yamada Y; Kadowaki T; Honda H; Yanagihara Y; Ito YM; Kameyama S; Ohta N; Hosoi T; Arai T; Sawabe M; Takeuchi T; Takahashi S; Kitamura T
Eur Urol; 2005 Nov; 48(5):752-9. PubMed ID: 16126332
[TBL] [Abstract][Full Text] [Related]
20. Differences in base excision repair capacity may modulate the effect of dietary antioxidant intake on prostate cancer risk: an example of polymorphisms in the XRCC1 gene.
van Gils CH; Bostick RM; Stern MC; Taylor JA
Cancer Epidemiol Biomarkers Prev; 2002 Nov; 11(11):1279-84. PubMed ID: 12433703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
